Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FluMos-v2 (National Institute of Allergy and Infectious Diseases)
- Development stage
- Unknown
- Lead developer
- Vaccine Research Center
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FluMos-v2 (VRC-FLUMOS0116-00-VP) is an experimental mosaic hexavalent influenza vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). It is designed to provide broad protection against multiple strains of influenza by displaying hemagglutinin (HA) proteins from six different influenza virus strains on a self-assembling nanoparticle scaffold. This mosaic approach aims to elicit a more diverse and potent immune response compared to traditional seasonal vaccines, potentially serving as a step toward a universal influenza vaccine. It is currently being evaluated in Phase I clinical trials for safety, tolerability, and immunogenicity in healthy adults.
- Other names
- VRC-FLUMOS0116-00-VPVRC-FLUMOS-0116-00-VPVRC-FLUMOS 0116-00-VPFluMos-v2FluMos-v-2FluMos-v 2mosaic hexavalent influenza vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on FluMos-v2 (National Institute of Allergy and Infectious Diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FluMos-v2 (National Institute of Allergy and Infectious Diseases).